BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aiello F, Gallo Afflitto G, Li JO, Martucci A, Cesareo M, Nucci C. CannabinEYEds: The Endocannabinoid System as a Regulator of the Ocular Surface Nociception, Inflammatory Response, Neovascularization and Wound Healing. J Clin Med 2020;9:E4036. [PMID: 33327429 DOI: 10.3390/jcm9124036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Diebold Y, García-Posadas L. Is the Conjunctiva a Potential Target for Advanced Therapy Medicinal Products? Pharmaceutics 2021;13:1140. [PMID: 34452098 DOI: 10.3390/pharmaceutics13081140] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chetoni P, Burgalassi S, Zucchetti E, Granchi C, Minutolo F, Tampucci S, Monti D. MAGL inhibitor NanoMicellar formulation (MAGL-NanoMicellar) for the development of an antiglaucoma eye drop. Int J Pharm 2022;:122078. [PMID: 35932931 DOI: 10.1016/j.ijpharm.2022.122078] [Reference Citation Analysis]
3 Di Zazzo A. Pathogenesis of the Homeostatic Failure of Ocular Surface as Morpho-Functional Unit. JCM 2022;11:4685. [DOI: 10.3390/jcm11164685] [Reference Citation Analysis]
4 Tran BN, Maass M, Musial G, Stern ME, Gehlsen U, Steven P. Topical application of cannabinoid-ligands ameliorates experimental dry-eye disease. Ocul Surf 2021;23:131-9. [PMID: 34922011 DOI: 10.1016/j.jtos.2021.12.008] [Reference Citation Analysis]
5 Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother 2021;146:112505. [PMID: 34891121 DOI: 10.1016/j.biopha.2021.112505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]